Alan Fuhrman Biography and Net Worth

CFO of Tyra Biosciences

Mr. Fuhrman is a veteran leader and board member in the biotechnology industry, with a proven track record of guiding companies through key periods of growth including late-stage clinical development, and strategic transactions with pharmaceutical partners, including mergers and acquisitions. Prior to joining TYRA, Mr. Fuhrman served as interim President, CEO and board member of Checkmate Pharmaceuticals, Inc. from October 2021 through February of 2022 and remained on the board of directors until its acquisition by Regeneron in May 2022. Prior to that, Mr. Fuhrman served as the Chief Financial Officer of Amplyx Pharmaceuticals, Inc. from December 2017 through June 2020. Before joining Amplyx, he served as CFO of Mirna Therapeutics, a publicly traded, clinical-stage microRNA company, that merged with Synlogic in August 2017. Mr. Fuhrman also served on the board of directors and as Chair of the Audit Committee for Loxo Oncology from January 2015 until its sale to Eli Lilly in February 2019. Mr. Fuhrman previously served as CFO of Ambit Biosciences, where he helped lead the company through its initial public offering and oversaw financial, investor and administrative operations until its sale to Daiichi Sankyo in January 2015. Earlier in his career, Mr. Fuhrman practiced as a certified public accountant with Coopers & Lybrand. He received a B.S. in both Business Administration and Agricultural Economics from Montana State University. Currently, he is a member of the board of directors of both SpringWorks Therapeutics and Esperion Therapeutics.

What is Alan Fuhrman's net worth?: The estimated net worth of Alan Fuhrman is at least $284.09 thousand as of October 30th, 2024. Fuhrman owns 12,849 shares of Tyra Biosciences stock worth more than $284,091 as of December 5th. This net worth evaluation does not reflect any other assets that Fuhrman may own. Additionally, Fuhrman receives an annual salary of $763,090.00 as CFO at Tyra Biosciences. Learn More about Alan Fuhrman's net worth.
How old is Alan Fuhrman?: Fuhrman is currently 67 years old. There are 6 older executives and no younger executives at Tyra Biosciences. The oldest executive at Tyra Biosciences is Dr. Robert L. Hudkins Ph.D., Chief Technology Officer, who is 68 years old. Learn More on Alan Fuhrman's age.
What is Alan Fuhrman's salary?: As the CFO of Tyra Biosciences, Inc., Fuhrman earns $763,090.00 per year. There are 2 executives that earn more than Fuhrman. The highest earning executive at Tyra Biosciences is Dr. Todd Harris Ph.D., Co-Founder, President, CEO, Secretary, Treasurer & Director, who commands a salary of $1,070,000.00 per year. Learn More on Alan Fuhrman's salary.
How do I contact Alan Fuhrman?: The corporate mailing address for Fuhrman and other Tyra Biosciences executives is 2656 STATE STREET, CARLSBAD CA, 92008. Tyra Biosciences can also be reached via phone at 619-728-4760 and via email at [email protected].. Learn More on Alan Fuhrman's contact information.
Has Alan Fuhrman been buying or selling shares of Tyra Biosciences?: Alan Fuhrman has not been actively trading shares of Tyra Biosciences over the course of the past ninety days. Most recently, on Wednesday, October 30th, Alan Fuhrman bought 9,500 shares of Tyra Biosciences stock. The stock was acquired at an average cost of $16.00 per share, with a total value of $152,000.00. Following the completion of the transaction, the chief financial officer now directly owns 12,849 shares of the company's stock, valued at $205,584. Learn More on Alan Fuhrman's trading history.
Who are Tyra Biosciences' active insiders?: Tyra Biosciences' insider roster includes Daniel Bensen (COO), Alan Fuhrman (CFO), Todd Harris (CEO), and Gilla Kaplan (Director). Learn More on Tyra Biosciences' active insiders.
Are insiders buying or selling shares of Tyra Biosciences?: In the last twelve months, insiders at the sold shares 10 times. They sold a total of 330,261 shares worth more than $5,972,313.26. The most recent insider tranaction occured on November, 21st when Director Robert J More sold 246,871 shares worth more than $4,999,137.75. Insiders at Tyra Biosciences own 15.2% of the company. Learn More about insider trades at Tyra Biosciences.
Information on this page was last updated on 11/21/2025.

Alan Fuhrman Insider Trading History at Tyra Biosciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
10/30/2024	Buy	9,500	$16.00	$152,000.00	12,849

Alan Fuhrman Buying and Selling Activity at Tyra Biosciences

Tyra Biosciences Company Overview

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.

Today's Range

Now: $22.11

$21.43

$22.13

50 Day Range

MA: $16.14

$12.97

$22.51

2 Week Range

Now: $22.11

$6.42

$22.83

Volume

916,903 shs

Average Volume

466,587 shs

Market Capitalization

$1.18 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.09

Alan Fuhrman Biography and Net Worth

What is Alan Fuhrman's net worth?

How old is Alan Fuhrman?

What is Alan Fuhrman's salary?

How do I contact Alan Fuhrman?

Has Alan Fuhrman been buying or selling shares of Tyra Biosciences?

Who are Tyra Biosciences' active insiders?

Are insiders buying or selling shares of Tyra Biosciences?